PRESENTATION TITLE

JAKi in Dermatology

PRESENTER(S)

Aaron R. Mangold, M.D., Associate Professor of Dermatology, Consultant and Research Chair in Dermatology and Director of the Clinical Trials Office, Mayo Clinic, Scottsdale Arizona

VIEWING LOCATIONS
Zoom Registration Link

LEARNING OBJECTIVES

• Describe the mechanism of Janus Kinase (JAK) inhibitors.
• Identify the current FDA approved indications for JAK inhibitors.
• Review the current literature of JAK inhibitors in Dermatology.

PRESENTERS BIO

Aaron R. Mangold, M.D., is an Associate Professor of Dermatology, Consultant and Research Chair in Dermatology and Director of the Clinical Trials Office at Mayo Clinic in Arizona. His research group is focused on translational studies in cancer diagnosis, rare inflammatory diseases, molecular disease prognosis, and novel therapeutics. Through this work, we have established large, well-annotated databases with multi-omic data in cancer and non-cancer. We have ongoing clinical trials and basic science studies in the clonal evolution of malignancy as it pertains to cutaneous lymphoma, melanoma, and cSCC. Additionally, we run rare disease translational trials with deep genomic profiling. To streamline, scale, and automate our work, we develop and leverage advanced genomic pipelines as well as have developed machine learning approaches to clinical, histological, and molecular diagnostics. Our team takes novel innovative approaches in clinical trials and translational medicine to accomplish these goals.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.